Company news

Larimar Therapeutics, Inc. news in 2021

Larimar Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results

November 11, 2021

Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress

August 18, 2021

Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results

August 11, 2021

Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing

May 24, 2021

Larimar Therapeutics Announces $95 Million Private Placement Financing

May 20, 2021

Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

May 19, 2021

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

May 10, 2021

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results

May 9, 2021

Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results

March 3, 2021

Decks in 2021